方盛制药：关于吲哚布芬片获得《药品注册证书》的公告

Core Viewpoint - The company has received approval from the National Medical Products Administration for its drug, Indobufene Tablets, allowing it to commence production [1] Group 1 - The company, Hunan Fangsheng Pharmaceutical Co., Ltd., has announced the receipt of a drug registration certificate [1] - The approval signifies a significant milestone in the company's drug development efforts [1]